ArticleCureus2025
Use of the RETeval™ Handheld Electroretinogram Device for Assessing the Risk of Diabetic Retinopathy in Patients With Type 1 Diabetes: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is the most common and severe ocular complication in diabetes. Significant advances in retinal electrophysiology have emerged in recent years in relation to diabetes-associated eye disease. Growing evidence of neuronal degeneration in DR has been established, most of which comes from electroretinography (ERG) studies. A five-year-old male patient with type 1 diabetes mellitus (T1D), under treatment since 2021, and a 15-year-old male patient with T1D, under treatment since 2019, underwent ERG testing using the RETeval™ device (LKC Technologies, Inc., Germantown, MD, USA) and the DR program. Hemoglobin A1c (HbA1c) levels were measured at regular intervals at the outpatient clinic. The patients obtained DR protocol scores of 21.4 and 26.0, respectively. The median HbA1c during the study period was 6.2% for the first patient and 8.2% for the second. The findings suggest that RETeval could have potential clinical utility in the assessment of visual function and the early detection of diabetic eye changes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.